Natera (NASDAQ:NTRA) Receives Overweight Rating from Stephens

Stephens reaffirmed their overweight rating on shares of Natera (NASDAQ:NTRA) in a research report sent to investors on Friday morning, Benzinga reports. They currently have a $125.00 price objective on the medical research company’s stock.

Other research analysts have also issued reports about the company. Piper Sandler upped their price target on Natera from $110.00 to $120.00 and gave the company an overweight rating in a research report on Tuesday, May 14th. Jefferies Financial Group initiated coverage on shares of Natera in a report on Monday, June 3rd. They set a buy rating and a $142.00 price target for the company. TD Cowen upped their price objective on shares of Natera from $123.00 to $137.00 and gave the company a buy rating in a research note on Friday, May 10th. BTIG Research increased their target price on shares of Natera from $125.00 to $135.00 and gave the stock a buy rating in a research report on Friday. Finally, The Goldman Sachs Group lifted their price target on Natera from $90.00 to $100.00 and gave the company a buy rating in a report on Monday, April 15th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $112.80.

Natera Trading Up 6.4 %

Shares of NASDAQ:NTRA traded up $6.87 during midday trading on Friday, reaching $114.57. The company had a trading volume of 4,125,245 shares, compared to its average volume of 1,404,851. The company has a fifty day simple moving average of $107.91 and a two-hundred day simple moving average of $95.38. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12. The firm has a market cap of $14.07 billion, a price-to-earnings ratio of -36.72 and a beta of 1.48. Natera has a 1-year low of $36.90 and a 1-year high of $117.39.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same quarter in the prior year, the firm earned ($0.97) EPS. The firm’s quarterly revenue was up 58.1% on a year-over-year basis. Research analysts predict that Natera will post -2.43 earnings per share for the current year.

Insider Buying and Selling

In other Natera news, CEO Steven Leonard Chapman sold 37,500 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $108.10, for a total transaction of $4,053,750.00. Following the completion of the transaction, the chief executive officer now owns 213,351 shares of the company’s stock, valued at approximately $23,063,243.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Natera news, CEO Steven Leonard Chapman sold 37,500 shares of Natera stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $108.10, for a total value of $4,053,750.00. Following the transaction, the chief executive officer now directly owns 213,351 shares of the company’s stock, valued at approximately $23,063,243.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Daniel Rabinowitz sold 1,057 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $108,627.89. Following the transaction, the insider now owns 206,400 shares of the company’s stock, valued at $21,211,728. The disclosure for this sale can be found here. In the last three months, insiders sold 88,387 shares of company stock valued at $9,547,136. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its position in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares in the last quarter. YHB Investment Advisors Inc. bought a new stake in shares of Natera during the first quarter valued at approximately $36,000. Principal Securities Inc. acquired a new position in shares of Natera in the fourth quarter valued at $32,000. Arcadia Investment Management Corp MI lifted its position in Natera by 47.8% in the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after purchasing an additional 174 shares during the period. Finally, Tobam acquired a new stake in Natera during the second quarter worth $74,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.